Hypoaldosteronism diagnostic criteria

Jump to navigation Jump to search

Hypoaldosteronism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypoaldosteronism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypoaldosteronism diagnostic criteria On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypoaldosteronism diagnostic criteria

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypoaldosteronism diagnostic criteria

CDC on Hypoaldosteronism diagnostic criteria

Hypoaldosteronism diagnostic criteria in the news

Blogs on Hypoaldosteronism diagnostic criteria

Directions to Hospitals Treating Hypoaldosteronism

Risk calculators and risk factors for Hypoaldosteronism diagnostic criteria

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

There is no established criteria for the diagnosis of hypoaldosteronism. However, a positive history of hypotension, muscle weakness and fatigue should raise suspicion for hypoaldosteronism. These patients should first be tested for serum potassium levels and later for plasma renin activity (PRA), serum aldosterone, and serum cortisol. Asymptomatic hypoaldosteronism can also be discovered on routine laboratory evaluations.

Diagnostic Criteria

References

  1. White PC (1997). "Abnormalities of aldosterone synthesis and action in children". Curr. Opin. Pediatr. 9 (4): 424–30. PMID 9300202.
  2. Peter M, Dubuis JM, Sippell WG (1999). "Disorders of the aldosterone synthase and steroid 11beta-hydroxylase deficiencies". Horm. Res. 51 (5): 211–22. PMID 10559665.
  3. Kuribayashi I, Nomoto S, Massa G, Oostdijk W, Wit JM, Wolffenbuttel BH, Shizuta Y, Honke K (2005). "Steroid 11-beta-hydroxylase deficiency caused by compound heterozygosity for a novel mutation, p.G314R, in one CYP11B1 allele, and a chimeric CYP11B2/CYP11B1 in the other allele". Horm. Res. 63 (6): 284–93. doi:10.1159/000087074. PMID 16024935.
  4. Raebel MA (2012). "Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers". Cardiovasc Ther. 30 (3): e156–66. doi:10.1111/j.1755-5922.2010.00258.x. PMID 21883995.
  5. Sadjadi SA, McMillan JI, Jaipaul N, Blakely P, Hline SS (2009). "A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers". Ther Clin Risk Manag. 5 (3): 547–52. PMC 2710386. PMID 19707264.
  6. Hirschman GH, Rao DD, Oyemade O, Chan JC (1976). "Renal tubular acidosis: practical guides to diagnosis and treatment". Clin Pediatr (Phila). 15 (7): 645–50. doi:10.1177/000992287601500716. PMID 776486.

Template:WH Template:WS